The accumulation of massive investments by German and international pharmaceutical companies in Germany has strengthened the position of the industry. Investment in research and production contributes to a spirit of optimism with high added value. At the same time, it is unclear whether the framework conditions for remuneration and reimbursement will remain constant and how competitive Germany will remain as a business location.
